3 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 3 separate news trends connected to Capricor Therapeutics, spanning July 27, 2026 through August 14, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 29 article observations and 26 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
Capricor Therapeutics' stock surges on news of a potential FDA lifeline for its Duchenne muscular dystrophy drug.
Capricor Therapeutics shares are plunging after FDA staff disputed the company's claims regarding Phase 3 success for its DMD cell therapy.
Capricor Therapeutics shares plunged after FDA staff flagged data and efficacy concerns regarding its Duchenne heart disease therapy.